The first vaccine to prevent cervical cancer and genital diseases caused by human papilla virus will be available in pharmacies of tomorrow with a price of € 464.58 for the three doses required.
The vaccine, marketed by Sarnoff Pasteur MSD under the name of the Girasol, protects against four types of human papilla virus (HPV), two that cause cervical cancer and two that cause diseases such as genital warts.
Only four strains of HPV cause 70-75 percent of infections that degenerate into cervical cancer, so women have never been infected with this virus will be vaccinated and immunized against most genital infections caused by HPV.
Full vaccination consists of three separate doses (intramuscular injection) must be given within six months and one year (the second dose two months after the first and third and last, from the sixth month).
HPV, the virus is very common and easily transmitted, especially through sexual transmission, is the cause of Europe’s 75 per cent of cervical cancers, 70 percent of vulgar and vaginal tumors and 90 percent of genital warts.
70 percent of sexually active people are exposed to the virus at some point in their lives, the importance of vaccination of girls before they have a relationship.
Because sexually transmitted HPV, most infections occur between 20 and 30 years of age, although the development of infection and cancer development usually takes about fifteen years, when women are between 40 and 45 years.
According to the existing epidemiological studies, cervical cancer is the second most common cause of death among European women between 15 and 44 years, and only in Spain each year affects about 2100 of which 740 died of Spain.
In addition, 54,000 injuries each year diagnosed with cancer and approximately 56,000 cases of genital warts.
Department of Health and Community Autonomy have decided to include the vaccine in children’s vaccination schedule; so that the NHS will subsidize the vaccine for girls between 11 and 14 years (still do not have a relationship and more effective vaccines.)
However, NHS vaccine will cost about € 300 (104 euros per dose), slightly cheaper than at the pharmacy.
In addition, women who are beyond the immunization schedule and have between 15 and 26 years can also be vaccinated if so determined by your doctor.
To Professor of Preventive Medicine and Public Health at the Universidad Rye Juan Carlos de Madrid, Angel Gil, the benefits of this vaccine offset the price, because the lesions and tumors caused by HPV fee every year to some 220 million euros of public health (cytology and hospitalization costs, among others).
Chief of Epidemiology and Cancer Registry, Catalan Institute of Oncology, Xavier Bosch, said the clinical trial more than 27,000 women (adolescents aged 9 to 15 years and women aged 16 to 26 years) in 33 countries around the world, has proven efficacy “almost one hundred percent” on cancer and diseases associated with HPV.